GlassScriptPhysician profile
Daniel Martin
NPI 1215390851
$8,199.64
in general payments reported to CMS, 2019-2025
30 companies · $5,454 in 2025
The $5,454 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $125 · 2022: $363 · 2023: $573 · 2024: $1,562 · 2025: $5,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,462 · Education: $1,250 · Travel and Lodging: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.35 |
| Education | $1,250.00 |
| Travel and Lodging | $877.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,062.82 | 2024-2025 | |
| Inspire Medical Systems, INC. | $1,390.26 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,250.60 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $537.85 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $329.76 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $276.29 | 2023-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.00 | 2021-2024 | Ofev |
| Harmony Biosciences LLC | $179.62 | 2022-2024 | Wakix |
| Insmed, INC. | $168.36 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $168.27 | 2023-2024 | Yupelri |
| Edwards Lifesciences Corporation | $149.76 | 2025 | Pascal |
| Grifols USA, LLC | $148.96 | 2024-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $148.02 | 2023-2025 | Tyvaso, Tyvaso |
| Axsome Therapeutics, INC. | $139.65 | 2023-2025 | Sunosi |
| Viatris Specialty LLC | $135.10 | 2025 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.23 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.83 | 2024-2025 | Glassia |
| Baxter Healthcare | $118.89 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $109.78 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $97.36 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $82.63 | 2024-2025 | Tezspire, Tavneos |
| Pfizer INC. | $80.53 | 2023-2025 | |
| Vifor Pharma, INC. | $39.55 | 2025 | Zemaira, Veltassa |
| Janssen Pharmaceuticals, INC | $35.89 | 2023-2024 | Xarelto |
| Verona Pharma, INC. | $29.97 | 2025 | Ohtuvayre |
| Shionogi INC | $19.54 | 2024 | Fetroja |
| Inogen, INC. | $16.03 | 2025 | |
| Philips North America LLC | $14.70 | 2024 | (Ak6) Vest Therapy |
| Chiesi USA, INC. | $14.61 | 2024 | Kengreal, Cleviprex |
| Paratek Pharmaceuticals, INC. | $13.78 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.